Yuting Ren1, Xueying Yu1, Bin Chen1, Hefei Tang1, Songtao Niu1, Xingao Wang1, Hua Pan1, Zaiqiang Zhang2. 1. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China. 2. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China. ttyy0142011@126.com.
Abstract
BACKGROUND: Vanishing white matter (VWM) is one of the most prevalent leukoencephalopathies and is caused by recessive mutations in gene eIF2B1-5. The onset may vary from an antenatal disorder that is rapidly fatal to an adult-onset disorder with chronic progressive deterioration. METHODS: Based on a comprehensive study of 14 juvenile/adult patients diagnosed in our department as well as a review of 71 previously reported cases of genetically confirmed juvenile/adult-onset VWM since 2001, we attempted to delineate the clinical symptoms, disease evolution, episodic aggravation, associated symptoms, MRI findings and genotypic characteristics of adult VWM. RESULTS: The onset age of neuropsychiatric symptoms was 23.4 ± 10.6 years, and the mean follow-up time was 8.1 ± 4.8 years. Major clinical symptoms included headache, epilepsy, cognitive decline, cerebellar ataxia, and urinary disturbances. Episodic aggravation was found in 42.9% of the patients in our series. Molecular studies revealed fourteen novel missense mutations. Diffuse abnormal signals characterized by T1-weighted hypointensity and T2-weighted hyperintensity were observed in the supratentorial white matter. CONCLUSIONS: The symmetrical leukoencephalopathy must be considered in patients of any age with premature ovarian failure or optic neuropathy. The VWM disease spectrum consists of characteristic imaging findings in combination with extremely wide variability in VWM patients.
BACKGROUND: Vanishing white matter (VWM) is one of the most prevalent leukoencephalopathies and is caused by recessive mutations in gene eIF2B1-5. The onset may vary from an antenatal disorder that is rapidly fatal to an adult-onset disorder with chronic progressive deterioration. METHODS: Based on a comprehensive study of 14 juvenile/adult patients diagnosed in our department as well as a review of 71 previously reported cases of genetically confirmed juvenile/adult-onset VWM since 2001, we attempted to delineate the clinical symptoms, disease evolution, episodic aggravation, associated symptoms, MRI findings and genotypic characteristics of adult VWM. RESULTS: The onset age of neuropsychiatric symptoms was 23.4 ± 10.6 years, and the mean follow-up time was 8.1 ± 4.8 years. Major clinical symptoms included headache, epilepsy, cognitive decline, cerebellar ataxia, and urinary disturbances. Episodic aggravation was found in 42.9% of the patients in our series. Molecular studies revealed fourteen novel missense mutations. Diffuse abnormal signals characterized by T1-weighted hypointensity and T2-weighted hyperintensity were observed in the supratentorial white matter. CONCLUSIONS: The symmetrical leukoencephalopathy must be considered in patients of any age with premature ovarian failure or optic neuropathy. The VWM disease spectrum consists of characteristic imaging findings in combination with extremely wide variability in VWM patients.
Authors: M S van der Knaap; P G Barth; F J Gabreëls; E Franzoni; J H Begeer; H Stroink; J J Rotteveel; J Valk Journal: Neurology Date: 1997-04 Impact factor: 9.910
Authors: Gerre Vermeulen; Rainer Seidl; Saadet Mercimek-Mahmutoglu; Jan J Rotteveel; Gert C Scheper; Marjo S van der Knaap Journal: Ann Neurol Date: 2005-04 Impact factor: 10.422
Authors: Marjo S van der Knaap; Carola G M van Berkel; Jochen Herms; Rudy van Coster; Martina Baethmann; Sakkubai Naidu; Eugen Boltshauser; Michèl A A P Willemsen; Barbara Plecko; Georg F Hoffmann; Christopher G Proud; Gert C Scheper; Jan C Pronk Journal: Am J Hum Genet Date: 2003-10-17 Impact factor: 11.025
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822
Authors: Prisca S Leferink; Nicole Breeuwsma; Marianna Bugiani; Marjo S van der Knaap; Vivi M Heine Journal: Glia Date: 2017-12-29 Impact factor: 7.452